Literature DB >> 17558337

HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients.

Saira S Mohammed1, Elaheh Aghdassi, Irving E Salit, Ghazal Avand, Morris Sherman, Maha Guindi, Jenny E Heathcote, Johane P Allard.   

Abstract

OBJECTIVE: To determine whether the clinical and metabolic features associated with nonalcoholic fatty liver disease (NAFLD) are similar between HIV-positive and HIV-negative male subjects.
METHODS: Twenty-six HIV-positive and 25 HIV-negative subjects with liver biopsy-proven NAFLD were compared for liver histology (extent of steatosis, steatosis grading, and fibrosis staging), blood biochemistry (glucose, insulin, C-peptide, hemoglobin A1c, and lipid profile), insulin resistance (IR) using a homeostasis model assessment, anthropometry (body mass index [BMI], waist circumference, and arm muscle area), dietary intake, and physical activity.
RESULTS: The 2 groups were similar for age, liver histology, and IR. HIV-positive patients had a lower BMI (26.3 +/- 0.5 vs. 30.2 +/- 1.0 kg/m; P = 0.001) and lower percentage of fat mass (19.4 +/- 0.9 vs. 22.7 +/- 1.2; P = 0.026) when compared with HIV-negative patients. Although caloric intake was similar between groups, HIV-positive patients had a higher physical activity level (8.3 +/- 1.6 vs. 4.1 +/- 0.8 units of exercise per day; P = 0.029). Blood triglycerides were significantly higher (3.14 +/- 0.39 vs. 1.86 +/- 0.20 mmol/L; P = 0.006) in HIV-positive patients.
CONCLUSION: Although NAFLD was similar between the 2 groups, HIV-positive patients had a lower BMI and were more physically active compared with HIV-negative patients. This may suggest that in HIV, NAFLD is associated with factors other than those related to body fatness, such as HIV infection and treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17558337     DOI: 10.1097/QAI.0b013e318074efe3

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  21 in total

Review 1.  Obesity and Weight Gain in Persons with HIV.

Authors:  Samuel S Bailin; Curtis L Gabriel; Celestine N Wanjalla; John R Koethe
Journal:  Curr HIV/AIDS Rep       Date:  2020-04       Impact factor: 5.071

2.  Fatty Liver in Hispanics with HIV.

Authors:  Jose D Debes; Leonardo G Marianelli; Natalia Frassone; Estefania Ballari; Maria Elena Castrillon; Lei Zhang; Paul R Bohjanen; David R Boulware
Journal:  AIDS Res Hum Retroviruses       Date:  2016-04-08       Impact factor: 2.205

Review 3.  Adipose Tissue in HIV Infection.

Authors:  John R Koethe
Journal:  Compr Physiol       Date:  2017-09-12       Impact factor: 9.090

Review 4.  Inflammation and Metabolic Complications in HIV.

Authors:  Kassem Bourgi; Celestine Wanjalla; John R Koethe
Journal:  Curr HIV/AIDS Rep       Date:  2018-10       Impact factor: 5.071

Review 5.  NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?

Authors:  Subada Soti; Kathleen E Corey; Jordan E Lake; Kristine M Erlandson
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

6.  Human immunodeficiency virus infection and the liver.

Authors:  Megan Crane; David Iser; Sharon R Lewin
Journal:  World J Hepatol       Date:  2012-03-27

7.  MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial).

Authors:  Veeral H Ajmera; Edward Cachay; Christian Ramers; Irine Vodkin; Shirin Bassirian; Seema Singh; Neeraj Mangla; Richele Bettencourt; Jeannette L Aldous; Daniel Park; Daniel Lee; Jennifer Blanchard; Adrija Mamidipalli; Andrew Boehringer; Saima Aslam; Olof Dahlqvist Leinhard; Lisa Richards; Claude Sirlin; Rohit Loomba
Journal:  Hepatology       Date:  2019-06-18       Impact factor: 17.425

8.  Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis.

Authors:  H Nina Kim; Robin Nance; Stephen Van Rompaey; Joseph C Delaney; Heidi M Crane; Edward R Cachay; Elvin Geng; Stephen L Boswell; Benigno Rodriguez; Joseph J Eron; Michael Saag; Richard D Moore; Mari M Kitahata
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-01       Impact factor: 3.731

9.  Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard.

Authors:  Veeral H Ajmera; Edward R Cachay; Christian B Ramers; Shirin Bassirian; Seema Singh; Richele Bettencourt; Lisa Richards; Gavin Hamilton; Michael Middleton; Katie Fowler; Claude Sirlin; Rohit Loomba
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

10.  Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?

Authors:  Andre J Jeyarajan; Raymond T Chung
Journal:  J Infect Dis       Date:  2020-11-27       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.